mifamurtide sodium hydrate

Mifamurtide protects mice against herpes simplex virus type 2. It also is a macrophage activator.

Mifamurtide (MTP-PE), an analog of muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide (MTP-PE) is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide (MTP-PE) is used in immunology and rare disease research, including osteosarcoma-related experimental models, where Mifamurtide (MTP-PE) is applied to study innate immune receptor activation, macrophage polarization, and NOD2-associated signaling pathways in cellular immune response systems.

Mifamurtide sodium is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults. It was approved in Europe in March 2009.

Mifamurtide TFA (MTP-PE TFA), a muramyl dipeptide (MDP) analog, acts as a nonspecific immunomodulator by activating macrophages and monocytes to stimulate the immune response. As an orphan agent and a specific NOD2 ligand, it is utilized as an insulin sensitizer and holds research potential in osteosarcoma [1][2][3].